In early summer, Qingdao is shaded by trees, and all things are beautiful together. The 9th East China Health Management Forum was grandly held from May 31 to June 2, 2024. Renowned experts and scholars from China's health management industry, as well as more than 600 health management colleagues, gathered together from an authoritative and professional perspective to directly explore the forefront and pioneering new achievements in the field of health management, discuss the latest progress in health management research, and bring about an exciting annual event.

At the precise early screening forum for tumors held on the afternoon of June 1st, Professor Jiang Sunfang, Director of the Health Management Center of Zhongshan Hospital Affiliated to Fudan University, delivered a keynote speech titled "Exploration and Practice of Community Early Screening for Liver Cancer Based on the Healthy Alliance Model". The speech focused on the epidemiology of chronic liver disease in China, the exploration and practice of community screening for liver cancer, and the empowerment of new technologies. The speech received enthusiastic feedback from the attending experts and scholars.

Director Jiang first pointed out that there are many high-risk individuals for liver cancer in China, and the prevention and treatment of liver cancer urgently need to be given attention. According to the spirit of the "Healthy China Action - Cancer Prevention and Control Action Implementation Plan (2023-2030)", it is necessary to further promote early cancer screening and diagnosis and treatment, build a hierarchical liver cancer screening system, and strengthen the promotion of research achievements in cancer prevention and control, in order to achieve the goal of achieving a 5-year overall cancer survival rate of 46.6% by 2030; And it is proposed that exploring new technologies and indicators, such as miRNA and other new liver cancer biomarkers or biomarker combinations, is an effective measure to achieve cancer prevention and control goals and build a healthy China.

She further introduced that the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) explicitly use miRNA7 as an early diagnostic marker for liver cancer, and mentions multiple times the significance of using seven miRNA combinations for early detection, diagnosis, and monitoring of primary liver cancer. The detection rate of the liver cancer diagnostic model based on seven miRNAs in plasma for very early liver cancer is as high as 86.1%, which is 30% higher than the traditional marker AFP; The sensitivity and specificity for AFP negative liver cancer were 77.7% and 84.5%, respectively, which were significantly better than the detection of traditional biomarkers (evidence level 1, recommendation A). For high-risk individuals with liver cancer, if nodules with an intrahepatic diameter of ≤ 1cm are found, if a definitive diagnosis cannot be made, imaging examinations can be conducted every 2-3 months for follow-up, combined with serum AFP, 7 microRNA combinations, etc. to confirm the diagnosis. In summary, miRNA7^TM can significantly improve the detection rate of very early liver cancer and is significantly superior to other traditional liver cancer biomarkers in recurrence monitoring, especially for AFP negative populations.

Subsequently, she introduced the regional exploration and practice of the "Zhongshan Health Alliance Model" for early screening of liver cancer - with Zhongshan Hospital as the core, in conjunction with 8 tumor specialty alliance hospitals and 18 community health service centers in the city to form the "1+8+18" Fudan Zhongshan Cancer Prevention and Treatment Network, working together to create a "screening prevention, diagnosis, treatment and visit" health alliance model, optimizing the 15 minute community health circle, leading the community and other medical units to implement homogeneous management, complementary advantages, and collaborative development, committed to providing residents with comprehensive and full cycle health services.

In addition, as a pilot project of the "proactive health management new model", the "Liver Love Yourself" large-scale liver cancer early screening public welfare activity of the Shanghai Health Action has recently been launched in Kangcheng Community, Minhang District. The aim is to promote the sinking of high-quality medical resources, improve the capacity of grassroots medical services, and enable more residents to enjoy convenient and high-quality medical services, achieving a transition from "passive medical treatment" to "active health" through the construction of a close medical consortium. The event is based on miRNA7™, the world's first liver cancer molecular detection product that has been approved. This advanced early detection technology and professional medical team have improved the integrated prevention and treatment system from tumor prevention, high-risk population screening to early diagnosis, standardized treatment, and rehabilitation services, effectively reducing the harm of liver cancer.

This forum unites and consolidates colleagues in the academic field of health management, and is an important platform to assist various health management institutions in high-quality development and effectively connect with future health management service needs. We believe in the future with the wider application and promotion of miRNA7™ in the field of health management will contribute to improving the early diagnosis rate and 5-year survival rate of liver cancer in China, effectively pushing forward the early detection threshold for cancer in China, and building a new perspective of health management highland.